Crazy things can happen with a stock with so few shares...When you take a stock with only about 3.9 million shares outstanding, for sake of argument, that only has a market cap of C$23.25 million and is trading at about 2/3 of its cash and then you unleash a series of news releases what could happen?
With the merger completed and the company optimized to be able to bring transformational products to market this can be valued as a pharma company. With the diagnostic already approved it already has its first FDA approved product and PGX could have its first approved product this year. This company is revenue generating.
The diagnostic could be worth more than the current market cap.
CZO's base business alone has traded at about twice the current market cap.The largest client has returned, powder formulations have been created and the avenanthramide malted technology was said to be being evaluated by a major potential client in February.
The $40 million yeast beta glucan immune booster plant had a C$100 million NPV.
Given PGX-YBG may be 5X more potent than spray dried yeast beta glucan, is the only inhalable yeast beta glucan, and can be combined with other drugs/bioactives it could transcend the conventional yeast beta glucan immune booster market and enter markets in the billions?
The CoQ10 market may be 4X the size of the yeast beta glucan market.
Avalyn raised C$80 million going into its Phase I fibrosis clinical trial. There was no COVID fibrosis at the time, PGX-YBG could work on fibrosis outside the lungs, PGX-YBG could work on lung cancer, and PGX-YBG could also be used to deliver other drugs.
Alginate is an established platform for drug delivery and PGX-Alginate has 90X the surface area allowing more loading capacity.
Gilles once said the non-steroidal anti-inflammatory market is worth $50 billion and avenanthramide could be CZO's most valuable product.
The NMOSD market is expected to be US$2.5 billion by 2028.